How you see the clinical path evolving: will tetra-agonists be positioned primarily for severe obesity first, or could they compete with existing dual/tri agonists in broader metabolic indications?
NAD+ and longevity-focused care NAD+ is one of the most talked-about options in the longevity space
Moreover, SGLT2is have been shown to reduce the incidence of cardiovascular and kidney disease in people with and without diabetes [5, 6], suggesting that these medications should be considered for prevention of cardiovascular and kidney disease, irrespective of HbA 1c levels
Lack of quality control: Since compounded drugs are not subject to the same rigorous FDA standards as commercially available drugs, their quality and potency can be inconsistent.Side effects of compounded drugs can include potential contamination due to poor compounding practices, incorrect dosage due to mixing errors, allergic reactions to added ingredients, and severe adverse events like infections, depending on the specific drug and compounding process, as compounded medications are not subject to the same rigorous FDA regulations as commercially available drugs